Medication info
Zabiam M Tablet 50/1000 mg (Sitagliptin Hydrochloride Monohydrate, Metformin Hydrochloride)

Zabiam M Tablet 50/1000 mg (Sitagliptin Hydrochloride Monohydrate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletSitagliptin Hydrochloride Hydrate›56.7mg / 1 tablet
Manufacturer / importer
Unimed Pharmaceutical Co., Ltd.
Appearance
Brown oval film-coated tablets
Packaging
60 tablets/box [10 T/PTP*6]
Approval status
Active

MFDS item code 202302025 · Approved 2023.06.30 · Insurance code 649508370

Summary

Main use
Improves blood glucose control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. Generally, take this medicine twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, or patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions, 2. Patients in whom this medicine must not be administered). 2. Patients receiving metformin: - For patients with inadequate glycemic control on metformin monotherapy, the recommended initial dose is the current metformin dose together with sitagliptin 50 mg twice daily (total daily dose 100 mg). - Patients switching from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients with inadequate glycemic control on combination therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial metformin dose should take the patient's blood glucose level and current dose into account. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral glucose-lowering agents to this medicine. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, use caution and ensure appropriate monitoring. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that could increase the risk of lactic acidosis, with the following dose adjustment. The starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment Because this medicine contains metformin, it should not be administered to patients with hepatic impairment (see Precautions, 2. Patients in whom this medicine must not be administered).

Ingredients

Manufacturer
Unimed Pharmaceutical Co., Ltd.

Efficacy & effects

Improves blood glucose control in patients with type 2 diabetes mellitus

View approved original text

This medication contains both sitagliptin and metformin, helping patients with type 2 diabetes manage blood sugar more effectively along with dietary management and exercise therapy. In other words, it assists in improving blood sugar levels when blood glucose control is difficult.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. Generally, take this medicine twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, or patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions, 2. Patients in whom this medicine must not be administered). 2. Patients receiving metformin: - For patients with inadequate glycemic control on metformin monotherapy, the recommended initial dose is the current metformin dose together with sitagliptin 50 mg twice daily (total daily dose 100 mg). - Patients switching from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients with inadequate glycemic control on combination therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial metformin dose should take the patient's blood glucose level and current dose into account. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral glucose-lowering agents to this medicine. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, use caution and ensure appropriate monitoring. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that could increase the risk of lactic acidosis, with the following dose adjustment. The starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment Because this medicine contains metformin, it should not be administered to patients with hepatic impairment (see Precautions, 2. Patients in whom this medicine must not be administered).

Precautions

This medication contains sitagliptin and metformin, aiding in blood sugar control. First, the sitagliptin component can, although rarely, cause serious allergic reactions, so if symptoms like skin rash or difficulty breathing occur, the medication should be discontinued immediately and a doctor consulted. Additionally, sitagliptin may cause pancreatitis, an inflammation of the pancreas. Patients should be closely monitored for persistent abdominal pain or vomiting while using this medication, and any abnormal symptoms should be reported to healthcare professionals. The metformin component can cause a rare complication called lactic acidosis, which can be very serious due to excessive buildup of lactic acid in the body. Immediate medical attention is required if symptoms such as sudden difficulty breathing, muscle pain, lethargy, or abdominal pain occur. This medication should not be administered to patients with severely impaired kidney function or those with acute heart disease, severe infections, or dehydration. It should also be temporarily discontinued before and after examinations using iodine contrast agents. Pregnant women or those who may become pregnant and breastfeeding mothers should not use this medication for safety reasons. During treatment, there is a risk of hypoglycemia, so especially when taken with other hypoglycemic agents, blood glucose changes should be carefully monitored, and appropriate actions should be taken immediately if hypoglycemic symptoms occur. It is also advisable to avoid alcohol during treatment, and regular blood tests and kidney function assessments should be conducted to check for abnormalities. If surgery is planned, this medication should be discontinued 48 hours prior to surgery and not resumed until kidney function returns to normal after surgery. Finally, safety and efficacy have not been established for children, so this medication is not recommended for individuals under 18 years of age. If these precautions are followed, this medication can help with blood glucose control.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 28 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • hypoglycemia
  • dermatitis
  • loss of appetite
  • weight loss
  • elevated liver enzymes
  • acute renal failure
  • rash
  • urticaria
  • cutaneous vasculitis
  • severe and disabling arthralgia
  • blistering pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • shortness of breath
  • unstable angina
  • dizziness
  • decreased appetite
  • gastrointestinal disturbances
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air exposure, and it is best kept at room temperature between 1 and 30 degrees Celsius. Proper storage can maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Brown oval film-coated tablets

Package unit

60 tablets/box [10 T/PTP*6]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.